54.13
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Precedente Chiudi:
$54.32
Aprire:
$54.275
Volume 24 ore:
1.49M
Relative Volume:
0.47
Capitalizzazione di mercato:
$4.92B
Reddito:
$170.10M
Utile/perdita netta:
$-239.59M
Rapporto P/E:
-19.33
EPS:
-2.8
Flusso di cassa netto:
$-191.20M
1 W Prestazione:
-6.01%
1M Prestazione:
-16.41%
6M Prestazione:
+21.61%
1 anno Prestazione:
+11.17%
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Nome
Crispr Therapeutics Ag
Settore
Industria
Telefono
(617) 315-4600
Indirizzo
BAARERSTRASSE 14, ZUG
Confronta CRSP con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
CRSP
Crispr Therapeutics Ag
|
54.13 | 5.24B | 170.10M | -239.59M | -191.20M | -2.80 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
388.94 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.38 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
443.64 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
677.32 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
308.63 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-02-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
2025-02-12 | Aggiornamento | TD Cowen | Sell → Hold |
2025-02-03 | Iniziato | H.C. Wainwright | Buy |
2024-08-06 | Reiterato | Needham | Buy |
2024-08-02 | Iniziato | Rodman & Renshaw | Buy |
2024-06-28 | Ripresa | Guggenheim | Neutral |
2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
2023-12-11 | Downgrade | TD Cowen | Market Perform → Underperform |
2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
2023-09-27 | Iniziato | Mizuho | Buy |
2023-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
2023-05-30 | Iniziato | William Blair | Outperform |
2023-04-13 | Iniziato | Cantor Fitzgerald | Overweight |
2023-03-21 | Iniziato | Bernstein | Mkt Perform |
2023-03-17 | Iniziato | Bryan Garnier | Buy |
2023-03-07 | Iniziato | Robert W. Baird | Neutral |
2022-10-11 | Iniziato | Morgan Stanley | Underweight |
2022-08-09 | Downgrade | Barclays | Overweight → Equal Weight |
2022-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
2022-04-28 | Iniziato | Credit Suisse | Neutral |
2021-12-07 | Iniziato | Cowen | Market Perform |
2021-10-19 | Iniziato | SVB Leerink | Outperform |
2021-06-14 | Aggiornamento | Citigroup | Sell → Neutral |
2021-04-21 | Aggiornamento | Jefferies | Hold → Buy |
2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
2020-12-10 | Reiterato | Chardan Capital Markets | Buy |
2020-12-10 | Downgrade | Jefferies | Buy → Hold |
2020-12-10 | Reiterato | Needham | Buy |
2020-12-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2020-10-23 | Iniziato | RBC Capital Mkts | Sector Perform |
2020-10-05 | Iniziato | BofA Securities | Buy |
2020-07-28 | Reiterato | Needham | Buy |
2020-07-14 | Iniziato | SunTrust | Buy |
2020-06-15 | Reiterato | Canaccord Genuity | Buy |
2020-03-05 | Iniziato | Stifel | Hold |
2020-02-03 | Downgrade | Evercore ISI | Outperform → In-line |
2019-11-19 | Aggiornamento | William Blair | Mkt Perform → Outperform |
2019-11-12 | Aggiornamento | Oppenheimer | Perform → Outperform |
2019-08-01 | Iniziato | Jefferies | Buy |
2019-07-26 | Iniziato | Canaccord Genuity | Buy |
2019-06-10 | Iniziato | ROTH Capital | Buy |
2019-04-12 | Iniziato | Evercore ISI | Outperform |
2019-03-14 | Iniziato | William Blair | Mkt Perform |
2019-01-28 | Downgrade | Goldman | Buy → Neutral |
2019-01-22 | Downgrade | Citigroup | Neutral → Sell |
Mostra tutto
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know - MSN
Watch for Trend Continuation in CRISPR Therapeutics AG Next WeekJuly 2025 Rallies & Free AI Powered Buy and Sell Recommendations - thegnnews.com
Vestmark Advisory Solutions Inc. Sells 18,728 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Bernstein Remains a Hold on Crispr Therapeutics AG (CRSP) - The Globe and Mail
Fox Run Management L.L.C. Acquires New Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors - MSN
What Makes Crispr Therapeutics Ag (CRSP) a Good Buy? - Yahoo Finance
EverSource Wealth Advisors LLC Purchases 84,708 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR-based therapies signal a new direction in tackling infectious diseases - Clinical Trials Arena
CRISPR Therapeutics AG Shows Support at Fibonacci Level2025 Key Highlights & Expert-Curated Trade Recommendations - sundaytimes.kr
Virtu Financial LLC Purchases New Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates - MSN
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns - Yahoo Finance
Benjamin Edwards Inc. Purchases 5,853 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Pattern Scan Adds CRISPR Therapeutics AG to WatchlistPrice Action & Weekly Breakout Stock Alerts - kangso.co.kr
Crispr Therapeutics AG: Stock Surge Amid Clinical Advances - TipRanks
Is CRISPR Therapeutics' (CRSP) Rising Net Loss a Sign of Bold Investment or Growing Pressure? - Yahoo Finance
Crispr Therapeutics shares rise 1.48% premarket after ReproCELL Incorporated receives ¥5.3 million in funding. - AInvest
Equities Analysts Offer Predictions for CRSP Q4 Earnings - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Crispr Therapeutics shares rise 3.12% intraday after Allogene Therapeutics' positive trial updates. - AInvest
Upgrading Crispr Therapeutics To Hold Ahead Of A Catalyst-Rich 2H 2025 - Seeking Alpha
Blair William & Co. IL Cuts Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics Bets Big On Gene-Editing Breakthroughs - Finimize
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Cetera Investment Advisers - MarketBeat
Crispr Therapeutics Faces Stock Dip Amid Promising Developments - MSN
Crispr Therapeutics shares rise 1.10% premarket after Metagenomi reported positive business updates and financial results. - AInvest
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? - Yahoo Finance
Chardan Capital Has Strong Estimate for CRSP FY2026 Earnings - MarketBeat
Westwood Holdings Group Inc. Reduces Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Research Analysts Issue Forecasts for CRSP FY2025 Earnings - MarketBeat
3 Monster Stocks in the Making to Buy Right Now - AOL.com
Barclays Forecasts Strong Price Appreciation for CRISPR Therapeutics (NASDAQ:CRSP) Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Given New $80.00 Price Target at HC Wainwright - MarketBeat
CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading - MSN
Q3 EPS Estimate for CRISPR Therapeutics Boosted by Analyst - MarketBeat
Leerink Partnrs Brokers Reduce Earnings Estimates for CRSP - MarketBeat
CRISPR Therapeutics AG Insider Buying: Douglas Treco Acquires 20,000 Shares - AInvest
CRISPR Therapeutics (NASDAQ:CRSP) Given "Buy" Rating at Chardan Capital - MarketBeat
Crispr Therapeutics Ag Azioni (CRSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Crispr Therapeutics Ag Azioni (CRSP) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Treco Douglas A | Director |
Aug 06 '25 |
Buy |
57.03 |
20,000 |
1,140,600 |
22,000 |
George Simeon | Director |
Jul 16 '25 |
Buy |
52.03 |
989,812 |
51,499,918 |
1,730,179 |
Patel Naimish | Chief Medical Officer |
May 29 '25 |
Sale |
35.94 |
3,932 |
141,316 |
6,068 |
Kulkarni Samarth | Chief Executive Officer |
Mar 21 '25 |
Sale |
41.23 |
10,031 |
413,578 |
195,085 |
Bruno Julianne | Chief Operating Officer |
Mar 21 '25 |
Sale |
41.23 |
1,714 |
70,668 |
10,544 |
Prasad Raju | Chief Financial Officer |
Mar 21 '25 |
Sale |
41.23 |
2,197 |
90,582 |
16,767 |
KASINGER JAMES R. | General Counsel and Secretary |
Mar 21 '25 |
Sale |
41.23 |
3,185 |
131,318 |
81,729 |
Prasad Raju | Chief Financial Officer |
Mar 17 '25 |
Sale |
41.80 |
3,762 |
157,252 |
12,714 |
Kulkarni Samarth | Chief Executive Officer |
Mar 11 '25 |
Sale |
42.42 |
9,973 |
423,055 |
180,890 |
Kulkarni Samarth | Chief Executive Officer |
Mar 12 '25 |
Sale |
43.32 |
4,462 |
193,294 |
185,428 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):